Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.